-+ 0.00%
-+ 0.00%
-+ 0.00%

PMV Pharma's Rezatapopt Shows 48% Response Rate in Phase 2 Platinum-Resistant Ovarian Cancer Trial

PUBT·11/20/2026 15:30:38
Listen to the news
PMV Pharma's Rezatapopt Shows 48% Response Rate in Phase 2 Platinum-Resistant Ovarian Cancer Trial
  • PMV Pharmaceuticals reported durable tumor responses in its pivotal Phase 2 PYNNACLE trial of rezatapopt in patients with TP53 Y220C-mutated advanced cancers.
  • Results support potential use in previously treated platinum-resistant or refractory ovarian cancer, with mostly mild or moderate treatment-related side effects.
  • The findings were presented today at the ENA 2026 conference in Barcelona.
  • A U.S. application for accelerated approval in platinum-resistant or refractory ovarian cancer is planned for the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMV Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611201030PRIMZONEFULLFEED9881875) on November 20, 2026, and is solely responsible for the information contained therein.